| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/19/20 | 8-K | Current report filing |
|
6 | |
| 11/13/20 | DRS | Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy |
|
137 | |
| 11/10/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 11/06/20 | 8-K | Current report filing |
|
8 | |
| 10/15/20 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
100 |
| 08/07/20 | 8-K | Current report filing |
|
5 | |
| 07/29/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 07/16/20 | 8-K | Current report filing |
|
7 | |
| 07/08/20 | D | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. |
|
5 | |
| 07/01/20 | 8-K | Current report filing |
|
5 |
Lexaria Bioscience Corp.
Lexaria Bioscience Corp.